Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397722 · ClinicalTrials.gov registry record · Phase 2
Treatment Of Patients With Social Anxiety Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 299
- Enrollment target
NCT00397722 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 299 participants.
The verdict
NCT00397722, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 299 participants
- Enrollment target
Study Summary
GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
Interventions
- DRUG paroxetine
- DRUG GW876008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2006-11-09 |
| Est. Completion | 2007-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397722
The ClinicalTrials.gov registry entry for NCT00397722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paroxetine is the first listed.
NCT00397722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00397722 about?
NCT00397722 is a clinical study titled "Treatment Of Patients With Social Anxiety Disorder". GW876008 is a drug which may change mans reaction to stress, by decreasing the fear, physical and behavior symptoms that people with SocAD experience in social situations.
What is the current status of trial NCT00397722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 299 participants. The study started on 2006-11-09. Estimated completion is 2007-09-05.
What interventions are being tested in trial NCT00397722?
The interventions under investigation include: paroxetine (DRUG), GW876008 (DRUG).
Who is sponsoring clinical trial NCT00397722?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.